Sleep Modulation to Treat Depression

Healthy Clinical Trial

Official title:

Auditory Closed-loop Modulation of Slow Wave Sleep to Treat Major Depressive Disorder

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06443216
• Other study ID #: 2023-01804
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: July 2026

Study information

• Verified date: May 2024
• Source: University of Geneva, Switzerland
• Contact: Christoph Nissen, Prof. Dr. med.
• Phone: +41.22.305.45.38
• Email: christoph.nissen[@]hug.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Current first-line treatments for major depression (antidepressants and psychotherapy) show a long latency to response, and less than half of all patients experience full remission with optimized treatment, indicating the need for new developments. The aim of this study is to extend and further develop a longstanding line of research of using sleep neurophysiology as a 'window to the brain' and treatment development in major depression. Particularly, this project is designed to test the feasibility, efficacy and mechanisms of action of a new sleep-based treatment technology.

Description:

The planned study is a single-centre, doubled-blind, randomized, sham controlled, repeated measures within-subject (stimulation and sham) study including patients with major depression and healthy controls, across four sleep laboratory nights (adaptation, baseline, stimulation and sham in counterbalanced order). The investigators will test the primary hypothesis that auditory-closed loop suppression of slow wave sleep will improve depressive clinical symptomatology compared to sham stimulation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• MDD according to ICD-10 criteria (F32.1/2, F33.1/2; i.e. unipolar depression) for patient group

Exclusion Criteria:

• Relevant psychiatric disorders (other than MDD for the patient group), such as organic psychiatric disorders, lifetime history of substance dependency or current substance abuse (smoking will be allowed for recruitment reasons), schizophrenia or other psychotic disorders, affective disorders including bipolar disorder, borderline personality disorder, autism or other severe psychiatric disorders

• Known pregnancy

• Unstable medical conditions, such as unstable cardiovascular or metabolic disorders, etc.

• Relevant neurological disorders, including epilepsy, stroke, etc.

• Organic sleep disorders including relevant sleep apnea (AHI>15/h), periodic limb movement disorder (PLMS index>5/h), Restless-Legs-Syndrome (RLS), narcolepsy, circadian rhythm disorder or shift work/ jet lag

• Intake of medication affecting the central nervous system (other than antidepressants and lithium in patients); patients receiving benzodiazepines or (es)ketamine will not be included

• Current brain stimulation treatment, such as electroconvulsive therapy (ECT), TMS or deep brain stimulation

• Contraindications for tDCS or TMS studies, including but not limited to metal in the head/ brain or epilepsy

• Hearing impairment or tinnitus (auditory stimulation study)

• Inability to follow the procedures of the study (for example due to language problems)

• Left-handedness

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Healthy
• Major Depressive Disorder

Intervention

Device:
• Auditory closed-loop stimulation
Auditory closed-loop suppression of slow wave sleep
• Sham stimulation
No auditory stimulation

Locations

Country	Name	City	State
Switzerland	University of Geneva	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
Christoph Nissen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montgomery Åsberg Depression Rating Scale	Measure of the severity of depressive symptomatology; The scores range between 0 to 60. The higher the score, the more symptamology of depression the subjects presents.	Up to three weeks